The Association of the British Pharmaceutical Industry (ABPI) has announced that Pinder Sahota has decided to step down as President of the ABPI.

ABPI stated that he has made this decision to “avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital work of the ABPI”.

Richard Torbett, Chief Executive, ABPI, said: “Pinder is a passionate advocate for the industry, and I want to thank him for his valuable contribution as ABPI President.

“I fully respect Pinder’s decision to step down as ABPI President which will in no way affect the ongoing case relating to Novo Nordisk. Any breach of the ABPI Code is taken extremely seriously and it is essential that all regulatory actions are robust, fair and transparent.”

ABPI Vice-President, Susan Rienow, Country President of Pfizer, will temporarily take on the roles and responsibilities of the ABPI President until a new President is chosen by the ABPI Board.

The association had appointed Sahota, general manager and corporate vice president of Novo Nordisk UK as its new president in April last year.

If you want to share your stories and/or experiences with us, please send an email to [email protected]